Medicine FAQ

Only 0.4 to 1% of oral semaglutide reaches the bloodstream, meaning over 99% is destroyed in the gut. The permeation enhancer SNAC (salcaprozate sodium) temporarily buffers stomach acid and fluidizes gastric cell membranes, allowing a small fraction of the peptide to cross. The oral 25mg daily dose requires approximately 280x more active ingredient than the equivalent weekly injection.

Foundayo (orforglipron) beat oral semaglutide on both HbA1c reduction and weight loss in the ACHIEVE-3 head-to-head trial at 52 weeks. However, cross-trial comparisons suggest oral Wegovy 25mg may produce greater weight loss (roughly 14% vs 12%), while Foundayo has the convenience advantage of no fasting requirements. Foundayo also had higher gastrointestinal discontinuation rates. ACHIEVE-3 compared against semaglutide 7mg and 14mg doses, not the higher 25mg Wegovy pill dose approved for obesity.

The GLP-1 market reached approximately $70 billion in combined Novo Nordisk and Eli Lilly revenue in 2025. Lilly's tirzepatide franchise (Mounjaro + Zepbound) generated $36.5 billion, surpassing Novo's semaglutide franchise at roughly $33 billion. Lilly holds 57% US GLP-1 market share as of mid-2025, up from 41% a year earlier.

Oral pills will likely expand the market rather than cannibalize injections. The statin precedent is instructive: after generic atorvastatin launched in 2011, total statin use expanded from 31 million to 92 million Americans by 2019, a 197% increase. Current GLP-1 penetration is under 5% of eligible US adults versus 35%+ for statins, implying large expansion as oral delivery lowers barriers to initiation, improves adherence, and reduces discontinuation.

Semaglutide's core US patent expires December 5, 2031, with formulation patents extending to 2033. International patents in Canada, China, India, and Brazil are expiring in 2026, opening the door to generic and biosimilar competition outside the US. Tirzepatide patents extend into the mid-2030s, giving Eli Lilly a structural advantage in the oral GLP-1 market.

Two oral GLP-1 pills are FDA approved for weight loss: Novo Nordisk's oral Wegovy pill (semaglutide 25mg), approved December 2025 and launched January 2026, and Eli Lilly's Foundayo (orforglipron), approved April 1, 2026. Behind them, Novo's oral amycretin enters Phase 3 in 2026, Structure Therapeutics' aleniglipron targets mid-2026 Phase 3 start, and Viking Therapeutics' VK2735 oral showed promising Phase 2 data but had high discontinuation rates.

Foundayo starts at $149 per month for the lowest dose for self-pay patients. Eligible commercially insured patients may pay as little as $25 per month with the Foundayo savings card. Eligible Medicare Part D individuals may be able to get Foundayo for $50 per month beginning July 2026. The oral Wegovy pill is priced at $149 to $299 per month depending on dose.

IsoDDE (Isomorphic Drug Design Engine) is a unified computational drug design system released by Isomorphic Labs on February 10, 2026. It runs protein structure prediction, ligand binding, affinity estimation, and pocket identification in concert. On the hardest protein-ligand prediction tasks, IsoDDE achieves a 50% success rate versus roughly 23% for AlphaFold 3. On antibody-antigen modeling it exceeds AlphaFold 3 by 2.3× and Boltz-2 by 19.8×. On binding affinity prediction it achieves a Pearson correlation of 0.85, beating the physics-based gold standard FEP+ at 0.78.

No. As of February 2026, no AI-discovered drug has received FDA approval. The most advanced AI-discovered candidate is Insilico Medicine's rentosertib (ISM001-055), which reached Phase IIa with positive results published in Nature Medicine in June 2025. Isomorphic Labs targets its first clinical candidates for late 2026.

AI-discovered molecules show 80-90% Phase I success rates, well above the historical 40-65% average, indicating AI designs safe, tolerable molecules. However, Phase II success rates remain roughly 40%, the same as traditionally discovered drugs. AI has not yet demonstrated it can predict clinical efficacy, only safety and pharmacokinetic properties. If both trends hold, end-to-end success rates could roughly double from 5-10% to 9-18%.

Isomorphic has signed partnerships with Eli Lilly ($45M upfront, $1.7B in milestones), Novartis ($37.5M upfront, $1.2B+ in milestones, expanded February 2025), and Johnson & Johnson (terms undisclosed, announced January 2026). Total disclosed value exceeds $4 billion, but the 50:1 ratio between milestone promises and actual upfront cash reflects pharma's caution about AI drug discovery outcomes.

Isomorphic leads on computational benchmarks but trails on clinical progress. Insilico Medicine has 10+ IND approvals across 31 programs and the most advanced clinical candidate (rentosertib, Phase IIa). Recursion, which absorbed Exscientia in a $688M merger, takes a phenomics-first approach with 65 petabytes of biological imaging data. Both own wet-lab infrastructure that Isomorphic lacks. Isomorphic's advantages are Alphabet-scale compute, the AlphaFold lineage, and its unified architecture.

Isomorphic sits within Alphabet's Other Bets segment, which posted a $3.6 billion operating loss in 2025 against Alphabet's $132 billion net income. Isomorphic raised a $600 million external round led by Thrive Capital in March 2025. Alphabet can sustain this investment indefinitely, which is itself a competitive advantage over cash-constrained biotech startups.

Isomorphic Labs CEO Demis Hassabis said at Davos 2026 that the company expects its first AI-designed drugs to enter clinical trials by the end of 2026, pushing back an earlier target of 2025. The company hired Dr. Ben Wolf as CMO in June 2025 and opened a Cambridge, Massachusetts office, signaling clinical-stage staffing.

CagriSema failed to meet its primary endpoint of non-inferiority to Eli Lilly's tirzepatide (Zepbound). CagriSema achieved 23.0% weight loss at 84 weeks versus 25.5% for tirzepatide on the on-treatment estimand, and 20.2% versus 23.6% on intention-to-treat. The 2.5 to 3.4 percentage point gap across both measures establishes clinical inferiority.

The decline compounded across multiple events: a July 2025 guidance cut on US pricing headwinds, 9,000 job cuts announced in September 2025, a February 2026 guidance for the first revenue decline in modern history (adjusted sales down 5-13%), and the CagriSema REDEFINE 4 failure on February 23, 2026. Structural pricing pressure from MFN, IRA negotiations, and international patent expiries drove the fundamental deterioration.

After the CagriSema selloff, Novo trades at roughly 11x forward earnings and roughly 8x EV/EBITDA, cheaper than Pfizer (9x PE), Merck (14x), AstraZeneca (20x), and AbbVie (17x). This represents a nearly 80% PE compression from the 2024 peak of approximately 50x and a roughly 40% discount to the pharma peer average of 19x forward PE.

The FDA decision on Eli Lilly's orforglipron, expected April-May 2026. Orforglipron is an oral non-peptide GLP-1 with no food restrictions or fasting requirements, which directly undercuts the Wegovy pill's brief first-mover advantage. Goldman Sachs projects orforglipron capturing 60% oral GLP-1 market share by 2030.

Likely yes, based on the REDEFINE 1 and 2 placebo-controlled data submitted in December 2025, with a decision expected late 2026. But launching a drug with proven clinical inferiority to the market leader is a very different commercial proposition than launching one with a credible superiority story.

The GLP-1 market is projected to reach $100-150 billion by 2030, and Novo at 11x earnings prices in a catastrophe. But near-term catalysts are thin: orforglipron approval could arrive any day, post-CagriSema analyst downgrades haven't landed yet, and Lilly is pulling ahead on efficacy, pipeline, oral convenience, and manufacturing. The problems are structural, not sentiment-driven.